US 7,465,751 B2Granted

1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists

AssigneeRanbaxy Laboratories Limited

InventorsAnita Mehta, Jang Bahadur Gupta, Pakala Kumara Savithru Sarma

Life of this patent

Estimating the term…

Loading patent…

Abstract

This invention generally relates to the derivatives of 1-substituted-3-pyrroli dines having the structure of Formula (I): The compounds of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to a process for the preparation of the compounds of the present invention. pharmaceutical compositions containing the compounds of the present invention and the methods for treating the diseases mediated through muscarinic receptors.

Claims2

Dependent claims

A compound selected from the group consisting of:

2-cyclopentyl-2-hydroxy-N-[(3S)-1-benzyl-pyrrolidin-3-yl]-2-phenyl acetamide;
2-cyclopentyl-2-hydroxy-N-[(3S)-1-[2-(1,3-benzodioxol-5-yl)ethyl]pyrrolidin-3-yl]-2-phenyl acetamide;
(3S)-1-[[2-(1,3-benzodioxol-yl)ethyl]pyrrolidin-3-yl]-2-cyclopentyl-2-(hydroxy)-2-phenyl acetate;
(3S)-1-[[2(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2-cyclopentyl-2-(hydroxy)-2-phenyl acetate;
(3S)-1-[(4-methyl-pent-3-enyl)pyrrolidin-3-yl]-2-cyclopentyl-2-(hydroxy)-2-phenyl acetate;
(3S)-1-[(4-trifluoromethylphenyl)sulfonyl]pyrrolidin-3-yl]-2-cyclopentyl-2-(hydroxy)-2-phenyl acetate;
(3S)-1-[(4-nitrophenyl)sulfonyl]pyrrolidin-3-yl]-2-cyclopentyl-2-(hydroxy)-2-phenyl acetate;
(3S)-1-benzyl-pyrrolidin-3-yl (2R)-2-hydroxy-2-(3-oxocyclopentyl)-2-phenyl acetate;
(3S)-1-benzyl-pyrrolidin-3-yl (2R)-hydroxy-2-(3-hydroxycyclopentyl)-2-phenyl acetate;
(3S)-1-[(phenyl acetyl)pyrrolidin-3-yl]-2-cyclopentyl-2-(hydroxy)-2-phenyl acetate;
(3S)-1-[(benzyloxy)acetyl)]pyrrolidin-3-yl]-2-cyclopentyl-2-(hydroxy)-2-phenyl acetate;
Benzyl (3S)-3-[(2-hydroxy-2-cyclopentyl-2-phenylpropanoyl)oxy]pyrrolidin-1-carboxylate;
(3S)-1-[(4-bromophenyl)sulfonyl]pyrrolidin-3-yl]-2-cyclopentyl-2-hydroxy)-2-phenyl acetate;
(3S)-1-benzyl-pyrrolidin-3-yl (2R)-cyclopental-2-(hydroxy)-2-phenyl acetate;
(3S)-1-[[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl](2R)-cyclopentyl-2-(hydroxy)-2-phenyl acetate;
and,
(3S)-1-[[2-(1,3-benzodioxol-5-yl)ethyl]pyrrolidin-3-yl](2R)-cyclopentyl-2-(hydroxy)-2-phenyl acetate.

14 more elements

Dependencies are inferred from the claim text.

Facts

Application: 10/540,245Filed 23 Dec 2002
Published: US 2006/0194862 A131 Aug 2006
Granted: 16 Dec 2008
Term ends: Not estimatedThe source records don’t support an estimate.

Classification9 codes

C07D 405/12
Containing two hetero rings: linked by a chain containing hetero atoms as chain links
A61P 3/04
Drugs for disorders of the metabolism: anorexiants; Antiobesity agents
A61P 3/10
For glucose homeostasis: for hyperglycaemia, e.g. antidiabetics
A61P 11/00
Drugs for disorders of the respiratory system

Family

US 2006/0194862 A1Pre-grant publication · published 31 Aug 2006
US 7,465,751 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key